Eric Halioua – VJRegenMed

Plasmacytoid dendritic cell-based cancer vaccines

Simon Ng — Tue, 03 May 2022 16:17:05 +0000

Eric Halioua, PDC*line Pharma, Liege, Belgium, provides an overview of PDC*line, a novel cell line derived from plasmacytoid dendritic cells (PDCs) in the bones of patients with leukemia. The cell line is more potent than allogeneic or autologous myeloid cells and are not rejected in humans. He additionally highlights the ease of manufacturing cancer vaccines from PDC*line due to the consistency of the cell line. This interview was conducted during Meeting on the Mediterranean 2022.

Developing a therapeutic cancer vaccine for patients with NSCLC

Simon Ng — Tue, 03 May 2022 16:17:04 +0000

Eric Halioua, PDC*line Pharma, Liege, Belgium, comments the development of PDC*lung, a novel therapeutic plasmacytoid dendritic cell (PDC)-derived vaccine for patients with non-small cell lung cancer (NSCLC). He describes the mechanism of action of the vaccine, where irradiated PDCs are loaded with peptides encoding various lung tumor antigens. A Phase I/II trial (NCT03970746) will assess the vaccine in 64 patients in either a high or low dose. This interview was conducted during Meeting on the Mediterranean 2022.

Assessing PDC*mel, dendritic cell-based vaccine in melanoma

Simon Ng — Tue, 03 May 2022 16:17:04 +0000

Eric Halioua, PDC*line Pharma, Liege, Belgium, discusses the development of PDC*mel, a plasmacytoid dendritic cell (PDC)-derived vaccine for patients with melanoma. The investigational therapy consists of PDC*line loaded with four melanoma peptides and have the ability to be stored in liquid nitrogen. He also describes a Phase I trial (NCT01863108), which tested the vaccine in three different doses. This interview was conducted during Meeting on the Mediterranean 2022.